Breast cancer management: opportunities and barriers to an individualized approach
- PMID: 21278437
- DOI: 10.1634/theoncologist.2011-S1-20
Breast cancer management: opportunities and barriers to an individualized approach
Abstract
A personalized approach to breast cancer management is increasingly possible with state of the art diagnostics and treatments. However, many challenges still exist in choosing the right therapeutic strategy and the right dosing for a specific patient population. Biomarkers such as estrogen receptor, progesterone receptor, and HER-2 status are used to tailor therapy, but success rates with targeted therapy suggest that appropriate patient populations still require greater definition. The introduction of the genomic era has likewise advanced the ability to offer a tailored approach to breast cancer management, but much work is still needed in this area as well. Microarray-based gene expression profiles have demonstrated initial promise, but we need a better understanding of more complex tumor signaling pathways. Strategies include annotated tumor specimens, next-generation gene sequencing, proteomics, and metabolomics. An individualized approach to breast cancer management has the potential to offer clear clinical benefits and the ability to bring more tailored, cost-effective strategies to the market. The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion.
Similar articles
-
Personalized oncology: recent advances and future challenges.Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Metabolism. 2013. PMID: 22999010 Review.
-
Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S13-7. doi: 10.1517/13543781003718858. Expert Opin Investig Drugs. 2010. PMID: 20374025
-
Individualized targeted therapy for glioblastoma: fact or fiction?Cancer J. 2012 Jan-Feb;18(1):40-4. doi: 10.1097/PPO.0b013e318243f6c9. Cancer J. 2012. PMID: 22290256 Review.
-
Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.S D Med. 2010 Jul;63(7):247-53. S D Med. 2010. PMID: 20666024
-
[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].Bull Cancer. 2013 Dec;100(12):1295-310. doi: 10.1684/bdc.2013.1856. Bull Cancer. 2013. PMID: 24225763 Review. French.
Cited by
-
Prediction of years of life after diagnosis of breast cancer using omics and omic-by-treatment interactions.Eur J Hum Genet. 2017 May;25(5):538-544. doi: 10.1038/ejhg.2017.12. Epub 2017 Mar 8. Eur J Hum Genet. 2017. PMID: 28272536 Free PMC article.
-
NT5E CpG island methylation is a favourable breast cancer biomarker.Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31. Br J Cancer. 2012. PMID: 22653144 Free PMC article.
-
Epigenetics advancing personalized nanomedicine in cancer therapy.Adv Drug Deliv Rev. 2012 Oct;64(13):1532-43. doi: 10.1016/j.addr.2012.08.004. Epub 2012 Aug 19. Adv Drug Deliv Rev. 2012. PMID: 22921595 Free PMC article. Review.
-
Insight into the heterogeneity of breast cancer through next-generation sequencing.J Clin Invest. 2011 Oct;121(10):3810-8. doi: 10.1172/JCI57088. Epub 2011 Oct 3. J Clin Invest. 2011. PMID: 21965338 Free PMC article. Review.
-
FOXQ1 is Differentially Expressed Across Breast Cancer Subtypes with Low Expression Associated with Poor Overall Survival.Breast Cancer (Dove Med Press). 2021 Mar 1;13:171-188. doi: 10.2147/BCTT.S282860. eCollection 2021. Breast Cancer (Dove Med Press). 2021. PMID: 33688250 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous